Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of CAP7.1 in Adult Patients with Refractory NSCLC, SCLC and Biliary Carcinoma
2012-002378-30Phase 2Completed
- Sponsor
- CellAct Pharma GmbH
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAP 7.1 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and cholangiocarcinoma (CCA), sponsored by CellAct Pharma GmbH. Primary endpoint: Disease control rate. Started Jun 2012; status: completed.
02
Drugs
CAP 7.1
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2012-002378-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002378-30.